ProfileGDS5678 / 1460603_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 91% 91% 92% 95% 91% 87% 86% 88% 89% 90% 90% 91% 91% 91% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 17.3410791
GSM967853U87-EV human glioblastoma xenograft - Control 27.4365191
GSM967854U87-EV human glioblastoma xenograft - Control 37.6146392
GSM967855U87-EV human glioblastoma xenograft - Control 48.5054195
GSM967856U87-EV human glioblastoma xenograft - Control 57.4639491
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 16.421687
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 26.3566786
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 36.7240488
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 47.0300689
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 17.319290
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 27.0961790
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 37.4135591
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 47.5138691
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 57.2987991